Rebound Thrombocytosis after Induction Chemotherapy is a Strong Biomarker for Favorable Outcome in AML Patients.
Journal
HemaSphere
ISSN: 2572-9241
Titre abrégé: Hemasphere
Pays: United States
ID NLM: 101740619
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
01
12
2018
accepted:
20
01
2019
entrez:
15
11
2019
pubmed:
15
11
2019
medline:
15
11
2019
Statut:
epublish
Résumé
Whereas the molecular events underlying acute myeloid leukemia (AML) are increasingly identified, dynamics of hematologic recovery following induction chemotherapy remain mysterious. Platelet recovery may vary between incomplete and excess recovery among patients achieving remission. We analyzed platelet recovery after the first induction cycle in 291 consecutive AML patients. We defined excess platelet rebound (EPR) as platelet increase above 500 G/L. We observed EPR in 120 (41.2%) patients. EPR+ patients had lower platelets at diagnosis, higher marrow infiltration, more frequently
Identifiants
pubmed: 31723819
doi: 10.1097/HS9.0000000000000180
pii: HEMASPHERE-2018-0213
pmc: PMC6746035
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e180Informations de copyright
Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.
Déclaration de conflit d'intérêts
The authors have indicated they have no potential conflicts of interest to disclose.
Références
J Clin Oncol. 1997 Jun;15(6):2262-8
pubmed: 9196139
Cancer. 1980 Apr 15;45(8):2017-29
pubmed: 6989483
N Engl J Med. 2016 Feb 4;374(5):422-33
pubmed: 26789727
Blood. 2010 Jan 21;115(3):453-74
pubmed: 19880497
J Clin Oncol. 2003 Dec 15;21(24):4642-9
pubmed: 14673054
Blood. 2006 Mar 15;107(6):2525-30
pubmed: 16317100
N Engl J Med. 2008 May 1;358(18):1909-18
pubmed: 18450602
J Clin Oncol. 2013 Nov 10;31(32):4123-31
pubmed: 24062403
J Clin Oncol. 2016 Feb 1;34(4):300-2
pubmed: 26668347
Hematol Oncol. 2018 Jun 3;:
pubmed: 29862539
Leukemia. 2015 May;29(5):1041-50
pubmed: 25428261
N Engl J Med. 2018 Mar 29;378(13):1189-1199
pubmed: 29601269
Nature. 1994 Jun 16;369(6481):568-71
pubmed: 8202159
Leuk Res. 2012 Nov;36(11):1325-9
pubmed: 22727508
Br J Cancer. 2011 Sep 27;105(7):970-4
pubmed: 21878938
J Clin Oncol. 2011 Feb 10;29(5):487-94
pubmed: 21220605
Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13576-81
pubmed: 23901108
Blood. 2012 Aug 23;120(8):1581-8
pubmed: 22649108
Blood. 2003 Jan 1;101(1):64-70
pubmed: 12393605
J Clin Oncol. 2017 Mar 20;35(9):934-946
pubmed: 28297624
J Clin Oncol. 2015 Apr 10;33(11):1258-64
pubmed: 25732155
J Clin Oncol. 2013 Nov 1;31(31):3889-97
pubmed: 24062400
Br J Haematol. 1999 Oct;107(1):69-79
pubmed: 10520026
Br J Haematol. 2015 Jan;168(2):268-73
pubmed: 25212255
Blood. 1996 Jan 15;87(2):567-73
pubmed: 8555478
Exp Hematol. 2016 Apr;44(4):297-302.e1
pubmed: 26733047
N Engl J Med. 2015 Sep 17;373(12):1136-52
pubmed: 26376137
Cell Stem Cell. 2007 Dec 13;1(6):685-97
pubmed: 18371409
N Engl J Med. 2012 Jul 5;367(1):11-9
pubmed: 22762314
Blood. 2016 Nov 3;128(18):2253-2257
pubmed: 27574191
Cell Stem Cell. 2007 Dec 13;1(6):671-84
pubmed: 18371408
J Clin Invest. 2002 Aug;110(3):389-94
pubmed: 12163458
Blood. 1995 May 15;85(10):2720-30
pubmed: 7742532